(Q34198055)

31 July 2017

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia (English)

1 reference

31 July 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

5

Jeffrey Szer

1 reference

31 July 2017

10

Robert Peter Gale

1 reference

31 July 2017

24

Joseph H Antin

1 reference

31 July 2017

23

David A Rizzieri

1 reference

31 July 2017

16

Edward A Stadtmauer

1 reference

31 July 2017

29

Mark R Litzow

1 reference

31 July 2017

22

Jane L Liesveld

1 reference

31 July 2017

9

Richard E Champlin

1 reference

31 July 2017

4

Sergio A Giralt

1 reference

31 July 2017

1

Stephanie J Lee

1 reference

31 July 2017

7

Ann E Woolfrey

1 reference

31 July 2017

14

Philip L McCarthy

1 reference

31 July 2017

33

Richard T Maziarz

1 reference

31 July 2017

6

Mukta Arora

1 reference

31 July 2017

15

Eduardo Olavarria

1 reference

31 July 2017

21

Gregory A Hale

1 reference

31 July 2017

27

Edward Copelan

1 reference

31 July 2017

25

Brian J Bolwell

1 reference

31 July 2017

11

Joerg Halter

1 reference

31 July 2017

12

Armand Keating

1 reference

31 July 2017

28

Osman Ilhan

1 reference

31 July 2017

31

Axel R Zander

1 reference

31 July 2017

Manisha Kukreja

2

1 reference

31 July 2017

Tao Wang

3

1 reference

31 July 2017

Francisco Cervantes

8

1 reference

31 July 2017

David I Marks

13

1 reference

31 July 2017

Manuel Abecasis

17

1 reference

31 July 2017

Vikas Gupta

18

1 reference

31 July 2017

H Jean Khoury

19

1 reference

31 July 2017

Biju George

20

1 reference

31 July 2017

Matthew H Carabasi

26

1 reference

31 July 2017

Harold C Schouten

30

1 reference

31 July 2017

Mary M Horowitz

32

1 reference

31 July 2017

language of work or name

English

0 references

publication date

29 July 2008

1 reference

31 July 2017

1 reference

31 July 2017

112

1 reference

31 July 2017

8

1 reference

31 July 2017

3500-3507

1 reference

How I treat chronic myeloid leukemia in the imatinib era.

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Tra

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

The effect of prior exposure to imatinib on transplant-related mortality.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multi

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2954751

Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations

28 October 2018

1 reference

12 December 2020

1 reference

12 December 2020

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

12 December 2020

Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia

1 reference

12 December 2020

10.1182/BLOOD-2008-02-141689

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference